Sanofi consensus picture on Euronext Paris, shares trade inside 52 week range

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 15:54.

Sanofi (FR0000120578) continues to attract analyst attention on Euronext Paris as new regulatory headlines meet an already dense consensus landscape. According to Investing.com, 23 analysts currently cover the stock with a Buy rating on average and a 12 month price target around 96.70 euros for the Paris listing. Analyst consensus data from Investing.com

What analyst surveys show

The consensus summary compiled by Investing.com lists 12 Buy recommendations, 11 Hold equivalents and no explicit Sell call, pointing to a broadly constructive stance on the French pharma group that is also a CAC 40 and Euro Stoxx 50 member. Consensus breakdown on Investing.com The same overview cites an average 12 month price target of 96.70 euros, implying a double digit percentage gap to the latest spot price in Paris at roughly 73.90 euros per share on June 26, 2026. Euronext Paris quote and news feed on MarketScreener

US oriented data platforms also show a relatively supportive analyst stance for the New York listed American Depositary Shares. MarketBeat cites 15 Wall Street analysts with a consensus Hold rating on the SNY ticker and a mean price target of 41.80 dollars, compared with a last close at the same level on June 25, 2026 on Nasdaq. Sanofi SNY analyst overview on MarketBeat

Fresh EU antitrust scrutiny

Alongside the analyst data, the stock has to digest a new regulatory headline from Brussels. MarketScreener reports that the European Commission opened an antitrust investigation into Sanofi on June 26, 2026, focusing on potential competition issues in specific pharmaceutical markets within the European Union, according to a dpa-AFX dispatch cited in the news stream. MarketScreener news item on the EU investigation The probe adds a regulatory risk layer that investors in other big pharma names such as Novartis, Roche or Pfizer also regularly confront when authorities review pricing or market access practices.

Despite this scrutiny, the MarketScreener trading overview shows Sanofi shares changing hands at around 73.92 euros on Euronext Paris early on June 26, 2026, up roughly 0.2 percent on the day and still about 10 percent below the 52 week high marked in prior months, leaving room between the current level and the consensus target corridor from 82 to 112 euros per share. Euronext Paris price and 52 week range on MarketScreener

The products behind the stock

Sanofi generates most of its revenue with prescription medicines and vaccines, with the asthma and COPD biologic Dupixent, co-developed with Regeneron, one of its current flagship products in immunology alongside a broad vaccines portfolio managed through Sanofi Vaccines. Sanofi product overview on the corporate website

Where the Paris listing trades today

The Sanofi shares (FR0000120578) trade on June 26, 2026 at 14:04 CEST on Euronext Paris at around 73.92 euros.

This article provides general, fact based information and does not constitute investment advice or a recommendation to buy or sell any financial instrument. All data were obtained from sources deemed reliable but cannot be guaranteed.